BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Market Potential | Uncover BioAtla's strategic partnership pursuits and upcoming data presentations, potentially catalyzing investor interest and validating its technology platform |
Financial Outlook | Analyze BioAtla's $61.7M cash position, providing runway for clinical programs amid no current revenue, with a $5 price target from JMP Securities |
Pipeline Progress | Delve into BioAtla's key assets: Evalstotug, Ozuriftamab, and Mecbotamab, showing encouraging response rates across multiple solid tumor indications |
Innovative Therapies | Explore BioAtla's Conditionally Active Biologics (CABs) and Antibody-Drug Conjugates (ADCs), poised to disrupt oncology with promising clinical results |
Metrics to compare | BCAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCABPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.0x | −1.3x | −0.6x | |
PEG Ratio | −0.06 | −0.04 | 0.00 | |
Price / Book | 3.2x | 1.1x | 2.6x | |
Price / LTM Sales | - | 3.6x | 3.3x | |
Upside (Analyst Target) | - | 304.7% | 45.3% | |
Fair Value Upside | Unlock | 21.6% | 6.1% | Unlock |